Anlotinib , Penpulimab Combined With SBRT for Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT05485350 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Anlotinib Hydrochloride
DRUG: penpulimab
RADIATION: SBRT

Sponsor

Peking University Third Hospital